AstraZeneca Plc (AZN) has some of the most promising experimental antibiotics in development. Even so, it’s thinking of exiting the business. Chief Executive Officer Pascal Soriot is considering all options for the medicines, including finding more experienced partners to develop them or selling them outright, he said in a telephone interview last week. Soriot is choosing to focus AstraZeneca’s resources on three broad areas where the company is strongest: cancer; heart disease and diabetes; and respiratory, inflammation and immune-system disorders.
Help employers find you! Check out all the jobs and post your resume.
